Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.

Curr Oncol · 2023 · PMC10742907 · PMID 38132385

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Immature OS of the MAGNITUDE and TALAPRO-2 trials also showed a trend towards improved OS in HRR m and biomarker-unselected mCPRC patients who received PARP inhibitors combined with NHT in the first-line setting, respectively.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.